Directly switching from Hemlibra (emicizumab) to Novo Nordisk‘s investigational Mim8 (denecimig) was well tolerated in adults and…
Articles by Steve Bryson, PhD
The blood-clotting protein factor VIII (FVIII) that’s missing or faulty in people with hemophilia A is flexible and adopts…
Sobi and Sanofi’s philanthropic organization, Foundation S, have announced an additional donation of up to 100 million international…
Children with hemophilia have problems with dynamic balance — the ability to maintain balance while moving — and an…
A greater range of motion before surgery is associated with better post-surgical outcomes for people with hemophilia who undergo…
A delayed diagnosis is common for people with acquired hemophilia A (AHA), according to a new study that found…
Prophylactic replacement therapy to prevent bleeds was more cost-effective than on-demand treatment of active bleeds for children and adolescents in…
Note: This story was updated July 30, 2024, to clarify patients participating in AFFINE had moderately severe to severe…
TU7710, an experimental treatment for managing bleeds in people with hemophilia who have inhibitors, demonstrated an average half-life that…
Efanesoctocog alfa, a long-lasting factor VIII (FVIII) replacement therapy, has now been approved in the European Union for…